chevron_leftBack
As of 6 June 2026, Evommune, Inc. has a market cap of $859.04M USD, ranking #11640 globally and #2252 in the United States.
It ranks #1061 in the Healthcare sector, and #398 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$859.04MUSD
Enterprise Value
$720.9MUSD
Revenue (TTM)
$13.0MUSD
EBITDA (TTM)
-$79.68MUSD
Net Income (TTM)
-$68.87MUSD
PS Ratio
66.8
PB Ratio
3.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Luis Pena
open_in_new
Employees
48
Founded
2020
IPO
06 Nov 2025
Website
evommune.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.8% | -12% | 7.5% | 16% | -9.5% | 15% |
Upcoming Earnings
Earnings Date
Thu, Jun 11
Earnings Time
bedtime
After Close
EPS Estimate
-$0.7500
Revenue Estimate
$1.36M
News
Loading...
EVMN Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
EVMN
ISIN: US30054Y1073
Shares Out.:
Shares Outstanding:
36.018M1
Shares Float:
19.244M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
23.85 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
89K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
64K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
42K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
32K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
17K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
14K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$324.68B
38K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
34K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
32K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$182.72B
21K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.65B
13K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.68B
13K%
80.96B GBP
|
14.6
|
chevron_leftBack